Image

A Novel Viscoelastic Test Based on Ultrasonic Guided Wave for Identifying Hyperfibrinolysis Rapidly

A Novel Viscoelastic Test Based on Ultrasonic Guided Wave for Identifying Hyperfibrinolysis Rapidly

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study compares the results of the existing fibrinolysis monitoring technology to the Ultrasound-based viscoelastic hemostasis analysis, a new method, using small amount of extra blood obtained during routine blood draws in surgery patients.

Description

Ultrasound-based viscoelastic hemostasis analysis is a novel POC diagnostic method, which is suitable for operating theatres and emergency rooms.

The novel viscoelastic hemostasis analysis uses ultrasound guided waves to characterize the dynamic changes in viscoelastic properties of a blood sample during coagulation and clot lysis, which will be an assay of hyperfibrinolysis for critically ill patients.

This single-center, prospective, observational pilot study will evaluate the analytical performance as well as compared to conventional viscoelastic testing methods.

Eligibility

PART 1

Inclusion Criteria:

        Subject is scheduled for surgery with general surgery Subject is 18 years or order Subject
        requires routine TEG measurement
        Exclusion Criteria:
        Subject with coagulation and fibrinolysis exceeding normal values based on laboratory tests
        (including prothrombin time, international normalized ratio, activated partial
        thromboplastin time, plasma fibrinogen concentration, D-dimer, platelet count, hemoglobin
        concentration, and hematocrit) Subject with any abnormal parameters detected by TEG Subject
        with a history of bleeding and thrombosis Subject who has taken any medications that may
        affect coagulation, platelet aggregation, or fibrinolysis within the past 10 days
        (including non-steroidal anti-inflammatory drugs and aspirin) Residual blood volume <1ml
        PART 2
        Inclusion Criteria:
        Subject is scheduled for surgery with general surgery Subject is 18 years or order Subject
        Subjects with detected hyperfibrinolysis (LY30>8%) or non-hyperfibrinolysis(LY30≤8%) based
        on TEG.
        Exclusion Criteria:
        Residual blood volume <1ml

Study details
    Hyperfibrinolysis

NCT06374953

Second Affiliated Hospital, School of Medicine, Zhejiang University

26 June 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.